Le Lézard14h
Pfizer's TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...
Astellas Pharma Inc.: U.S. FDA Approves Expanded Label for Astellas' IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy
IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...
Orthopedics This Week9h
When Surgery Isn’t an Option, This Knee Tumor May Still Be Treated
Your patient presents with pain, swelling and impaired knee function. One rare diagnosis is non-malignant tenosynovial giant ...